Results 231 to 240 of about 32,890 (266)

Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero.

Clinical Gastroenterology and Hepatology
BACKGROUND AND AIMS Vedolizumab and ustekinumab pharmacokinetics in pregnancy and the infant following in-utero exposure remain incompletely defined. We aim to define the antenatal stability of ustekinumab and vedolizumab levels and the time at which ...
R. Prentice, E. Flanagan, E. Wright, Peter R. Gibson, Sam Rosella, O. Rosella, Jakob Begun, Yoon-Kyo An, I. Lawrance, Michael A Kamm, Miles P Sparrow, R. Goldberg, L. Prideaux, S. Vogrin, K. V. Kiburg, A. Ross, Megan Burns, Sally J. Bell   +17 more
semanticscholar   +1 more source

Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.

The Lancet Rheumatology, 2023
BACKGROUND The role of methotrexate in combination with biological agents in patients with psoriatic arthritis remains unclear. The MUST phase 3b trial aimed to compare the efficacy of ustekinumab plus placebo with ustekinumab plus methotrexate in ...
M. Koehm, T. Rossmanith, A. Foldenauer, E. Herrmann, J. Brandt-Jürgens, G. Burmester, H. Kellner, U. Kiltz, D. Kofler, J. Rech, Sorwe Mojtahed-Poor, C. Jonetzko, H. Burkhardt, F. Behrens   +13 more
semanticscholar   +1 more source

EFFICACY AND SAFETY OF USTEKINUMAB FOR CHRONIC POUCHITIS: A PROSPECTIVE OPEN-LABEL MULTICENTER STUDY.

Clinical Gastroenterology and Hepatology
BACKGROUND AND AIMS Seventeen percent of patients with ulcerative colitis that undergo proctocolectomy with pouch surgery will develop chronic pouchitis. We evaluated the efficacy of ustekinumab for these patients.
A. Outtier, Edouard Louis, O. Dewit, C. Reenaers, G. Schops, M. Lenfant, Emilie Pontus, Gert de Hertogh, B. Verstockt, J. Sabino, S. Vermeire, M. Ferrante   +11 more
semanticscholar   +1 more source

The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium

American Journal of Gastroenterology, 2022
INTRODUCTION: We evaluated the real-world effectiveness and safety of ustekinumab (UST) in patients with Crohn's disease (CD). METHODS: This study used a retrospective, multicenter, multinational consortium of UST-treated CD patients.
Amanda M Johnson, M. Barsky, W. Ahmed, Samantha Zullow, J. Galati, V. Jairath, N. Narula, F. Peerani, B. Click, Elliot S Coburn, T. Dang, S. Gold, M. Agrawal, R. Garg, M. Aggarwal, D. Mohammad, B. Halloran, G. Kochhar, Hannah Todorowski, Nabeeha Mohy Ud Din, J. Izanec, A. Teeple, C. Gasink, E. Muser, Z. Ding, A. Swaminath, Komal Lakhani, Daniel Hogan, Samit K. Datta, R. Ungaro, B. Boland, M. Bohm, M. Fischer, S. Sagi, A. Afzali, T. Ullman, G. Lawlor, D. Baumgart, Shannon Chang, D. Hudesman, D. Lukin, E. Scherl, J. Colombel, B. Sands, C. Siegel, M. Regueiro, W. Sandborn, D. Bruining, S. Kane, E. Loftus, P. Dulai   +50 more
semanticscholar   +1 more source

Treatment persistence among bio-naïve patients with Crohn’s disease initiated on ustekinumab or adalimumab

Current Medical Research and Opinion, 2023
Objectives To compare persistence and describe dose titration among bio-naïve patients with Crohn’s disease (CD) initiated on ustekinumab or adalimumab.
M. Zhdanava, Z. Ding, A. Manceur, E. Muser, P. Lefebvre, C. Holiday, M. Lafeuille, D. Pilon   +7 more
semanticscholar   +1 more source

Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long-term extension results.

Journal of Pediatric Gastroenterology and Nutrition - JPGN
OBJECTIVES To assess the efficacy, safety, immunogenicity, and pharmacokinetics through 240 weeks of ustekinumab treatment in paediatric patients from the long-term extension (LTE) of the phase 1, double-blind UniStar trial. METHODS Paediatric patients
Dan Turner, J. Rosh, Stanley A. Cohen, A. Griffiths, J. Hyams, J. Kierkus, O. Adedokun, Richard S Strauss, Lilianne Kim, Sheri Volger   +9 more
semanticscholar   +1 more source

Real-world comparison of the effectiveness between ustekinumab and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.

Journal of Crohn's & Colitis
BACKGROUND Both vedolizumab and ustekinumab can be considered for the treatment of ulcerative colitis (UC) but head-to-head trials are lacking. AIM We aimed to compare the effectiveness of vedolizumab and ustekinumab after anti-TNF failure in UC ...
M. Fumery, M. Serrero, G. Bouguen, A. Amiot, R. Altwegg, M. Nachury, L. Vuitton, X. Treton, L. Caillo, B. Pereira, A. Buisson   +10 more
semanticscholar   +1 more source

Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU.

Digestive and Liver Disease
BACKGROUND The efficacy of ustekinumab and vedolizumab for treating complex perianal fistula in Crohn's disease has been barely studied. We aimed to assess treatment persistence, clinical remission, and safety of these drugs in this context.
M. Casanova, B. Caballol, M. J. García, F. Mesonero, C. Rubín de Célix, P. Suárez-Álvarez, R. Ferreiro-Iglesias, M. M. Martín-Rodríguez, R. de Francisco, Pilar Varela-Trastoy, G. Bastida, M. Carrillo-Palau, A. Núñez-Ortiz, Patricia Ramírez-de la Piscina, D. Ceballos, Daniel Hervías-Cruz, Roser Muñoz-Pérez, B. Velayos, F. Bermejo, D. Busquets, Manuel Cabacino, Patricia Camo-Monterde, I. Marín-Jiménez, Carmen Muñoz, Luisa de la Peña-Negro, Eva Sierra-Moros, J. Barrio, E. Brunet-Mas, L. Bujanda, F. Cañete, F. Gomollón, N. Manceñido-Marcos, I. Rodríguez-Lago, M. C. Rodríguez-Grau, B. Sicilia, Sandra Torra-Alsina, L. Arranz-Hernández, Daniel Carpio, M. García-Sepulcre, C. González-Muñoza, J. Huguet, L. Márquez-Mosquera, María Pilar López-Serrano, Ángel Ponferrada-Díaz, María Chaparro, J. P. Gisbert   +45 more
semanticscholar   +1 more source

Ustekinumab

Reactions Weekly, 2022
  +4 more sources

Ustekinumab

Reactions Weekly, 2023
  +5 more sources